TriSalus (TLSI) Director Granted 15,000 Stock Options at $5.50

Form 4 filing overview: On June 12 2025, TriSalus Life Sciences, Inc. (TLSI) granted Director Gary B. Gordon a non-qualified stock option covering 15,000 shares of common stock at an exercise price of $5.50 per share.

Rhea-AI Filing Summary

Form 4 filing overview: On June 12 2025, TriSalus Life Sciences, Inc. (TLSI) granted Director Gary B. Gordon a non-qualified stock option covering 15,000 shares of common stock at an exercise price of $5.50 per share. The option expires on June 11 2035.

Vesting terms: The option will become fully vested on the earlier of (i) the one-year anniversary of the grant date (June 12 2026) or (ii) the date of TLSI’s next annual stockholder meeting, provided Mr. Gordon remains in service through such date.

Post-transaction ownership: Following the grant, Mr. Gordon beneficially owns 56,250 derivative securities (stock options) in TLSI, all held directly. No changes in non-derivative share ownership were reported.

Key takeaways for investors: • This is a routine incentive grant to a board member, aligning director compensation with shareholder interests.
• No open-market purchases or sales were disclosed; therefore, the filing does not signal immediate sentiment regarding TLSI’s current share price.
• The grant size is modest and is unlikely to have a material impact on the company’s capitalization or insider ownership structure.

Insights

Financial Analyst

TL;DR: Routine 15k-share option grant; neutral signal, aligns director incentives, no cash transactions.

The filing documents a standard board compensation award—15,000 options at $5.50 strike, expiring in ten years. Such grants are common for small-cap life science firms and do not alter cash flow, share count, or voting power until exercised. No accompanying share sale or purchase limits interpretive value. The vesting schedule encourages at least one year of board continuity. Overall, the disclosure neither strengthens nor weakens the investment thesis for TLSI and carries negligible dilution risk if exercised (≈0.1% of basic shares, assuming a ~15 million share count). Impact considered neutral.

Insider Trade Summary

Grant/Award: 15,000 shares

Grant/Award 1 txn

Insider Gordon Gary B.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (right to buy)	15,000	$0.00	$0.00

Holdings After Transaction: Director Stock Option (right to buy) — 56,250 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option shall fully vest on the one-year anniversary of the grant date of June 12, 2025, provided that the shares subject to the option will in any case be fully vested on the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person's continued service with the Issuer.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did TriSalus (TLSI) report on Form 4?

TLSI granted Director Gary B. Gordon an option to purchase 15,000 shares at $5.50 per share on 06/12/2025.

When do Gary B. Gordon’s TLSI options vest?

The options fully vest on the earlier of June 12 2026 or TLSI’s next annual stockholder meeting, subject to continued service.

What is the expiration date of the newly granted TLSI options?

The options expire on June 11 2035.

How many derivative securities does Gary B. Gordon own after the transaction?

He beneficially owns 56,250 TLSI stock options following the grant.

Did the Form 4 report any open-market purchases or sales of TLSI common stock?

No. The filing only reported an option grant; no shares were bought or sold.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/27/2025 - 04:26 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gordon Gary B.

(Last) (First) (Middle)

6272 W. 91ST AVENUE

(Street)

WESTMINSTER CO 80031

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TriSalus Life Sciences, Inc. [ TLSI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (right to buy)	$5.5	06/12/2025		A		15,000		(1)	06/11/2035	Common Stock	15,000	$0	56,250	D

Explanation of Responses:

1. The shares subject to the option shall fully vest on the one-year anniversary of the grant date of June 12, 2025, provided that the shares subject to the option will in any case be fully vested on the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person's continued service with the Issuer.

Remarks:

	/s/ Mary Szela, Attorney-in-Fact	06/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.